SynthesisFrontiers in pharmacology2026
Clinical utility of therapeutic drug monitoring of sertraline: a transdiagnostic systematic scoping review.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Clinical utility of therapeutic drug monitoring of sertraline: a transdiagnostic systematic scoping review.Frontiers in pharmacology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Therapeutic drug monitoring (TDM) is the quantification and interpretation of drug concentrations in blood to personalize pharmacotherapy. Dose adjustment of sertraline is currently based on clinical judgment. Preliminary evidence shows relationships between sertraline blood concentration and clinical outcomes. This review aims to evaluate the clinical utility of TDM of sertraline. Methods: A comprehensive, systematic search of studies in several databases was conducted up to 2025/06/26 on the potential relationship between TDM of sertraline and measures of efficacy, safety and tolerability. The search identified 5 clinical trials and 5 observational studies (N = 1106). Results: The included studies are highly heterogeneous. Most of the results are observational, mainly focused on depression and obsessive-compulsive disorder, covering the whole dosage range, with populations representing the whole life-span, observational periods from 4 weeks to 1 year. Efficacy assessments utilized diverse scales and heterogeneous measures of safety/tolerability. Most of the studies do not detect concentration-effect relationships. Preliminary, non-linear concentration-effect relationships are reported for efficacy and tolerability. Conclusion: There is no sufficient evidence for the clinical utility of a generalized use of TDM for sertraline. Preliminary evidence suggests associations between blood concentrations of sertraline and clinical outcomes, potentially supporting the utility of its TDM as guide for clinical judgement in the treatment of depression and obsessive-compulsive disorder, particularly in populations with specific risks. Further studies using symptom-specific clinical scales are needed to assess the potential clinical utility of sertraline TDM in personalized medicine. Systematic Review Registration: https://osf.io/84trm/overview.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.